Acquisition - June 15, 2026
Pelago Bioscience acquires RG Discovery
By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization, the company states.
Clinical Trials - June 15, 2026
SynAct announces positive Phase 2b results
SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.
Careers article - June 14, 2026
Hey there: Johnny Mogensen, new Director of NordForsk
Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.
Career choice - June 14, 2026
Postdoc Interview: “Just like in life, there is no single correct path in science”
Lionel Leck's research focuses on pediatric cancer, particularly neuroblastoma – one of the most commonly diagnosed childhood cancers with a poor prognosis.
In a new job - June 12, 2026
Hansa Biopharma appoints VP Business Development
Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development effective August 17.
Agreement - June 12, 2026
Xbrane Biopharma and JOINN Biologics US enter strategic partnership
The two companies have entered into a strategic partnership featuring customized development services for Xdarzane, Xbrane's biosimilar candidate referencing Darzalex (daratumumab).
